Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights November 12, 2026
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai October 21, 2026
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA September 24, 2026